Seoul Bio Hub, a bio-medical startup support platform established by the Seoul Metropolitan Government and jointly operated by the Korea Institute of Science and Technology and Korea University, is recruiting participating companies for the '2025 Seoul-Roche Diagnostics Startup Sprint Demo Day' together with global healthcare company Roche Diagnostics (Korea and APAC) until August 1.
This program was designed to discover startups with technology and business potential in the bio and medical fields and provide joint business development opportunities with Roche Diagnostics to support their entry into the global market. The companies that are finally selected will be given a research grant of 30 million won and the opportunity to reside in Seoul Bio Hub for one year, and will also be provided with opportunities for partnering with Roche Diagnostics experts and global network connections.
This year, the Korea Medical Device Development Foundation (KMDF) will also participate to support the participation of excellent domestic companies in the program. The recruitment areas are a total of five areas: blood-based algorithms, smart laboratories, digital pathology, digital PCR, and pharmacokinetic reports, focusing on AI, automation, data-based analysis technologies, and connections with Roche Diagnostics businesses.
Applicants must be companies that have been in business for less than 10 years, have a prototype, and aim to enter the global market. All applicants must submit a proposal that includes a collaboration plan with Roche Diagnostics along with IR materials.
The selection will be conducted through a first document evaluation and a second presentation evaluation, and six companies will be selected based on their technical skills, business potential, and global capabilities through the document evaluation. The final presentation evaluation will be held on September 10th at the Demo Day site.
Last year's Demo Day winner, SevenpointOne, developed the AI-based dementia screening solution 'AlzWIN' and successfully registered as a class 2 medical device from the FDA and achieved its first export. It is currently in the process of attracting 1.5 billion won in bridge investment and discussing follow-up investments with global investors. In Korea, it was officially adopted by the Dementia Care Center and received confirmation clinical approval from the Ministry of Food and Drug Safety.
Through this program, Seoul Biohub plans to continuously create successful cases of collaboration like Seven Point One and support participating companies to expand business opportunities by interacting with investors, industry, hospital officials, and the media.
Kim Hyun-woo, head of the Seoul Bio Hub Center, said, “This program is not just a simple startup competition; it is a platform that connects domestic innovative technologies to achieve results on the global stage.” He added, “We hope that Korean bio startups will create new growth opportunities by collaborating with global diagnostic companies.”
- See more related articles
You must be logged in to post a comment.